140 related articles for article (PubMed ID: 32978901)
1. Cost-utility analysis of adjuvant chemotherapy after concurrent chemoradiation in patients with locally advanced cervical cancer.
Rongsriyam K; Tangjitgamol S; Leelahavarong P; Teerawattananon Y; Tharavichitkul E; Tovanabutra C; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara LCA; Hanprasertpong J; Khunnarong J; Chottetanaprasith T; Lorvidhaya V
J Med Imaging Radiat Oncol; 2020 Dec; 64(6):873-881. PubMed ID: 32978901
[TBL] [Abstract][Full Text] [Related]
2. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of treatments for stage IB cervical cancer.
Katanyoo K; Praditsitthikorn N; Tangjitgamol S; Manusirivithaya S; Supawattanabodee B
J Gynecol Oncol; 2014 Apr; 25(2):97-104. PubMed ID: 24761212
[TBL] [Abstract][Full Text] [Related]
4. The Therapeutic Value of Adjuvant Chemotherapy after Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer.
Wang YN; Zhong ML; Liang MR; Yang JT; Zeng SY
Gynecol Obstet Invest; 2023; 88(5):286-293. PubMed ID: 37497957
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
Tangjitgamol S; Tharavichitkul E; Tovanabutra C; Rongsriyam K; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara A; Hanprasertpong J; Chomprasert K; Wanglikitkoon S; Atjimakul T; Pariyawateekul P; Katanyoo K; Tanprasert P; Janweerachai W; Sangthawan D; Khunnarong J; Chottetanaprasith T; Supawattanabodee B; Lertsanguansinchai P; Srisomboon J; Isaranuwatchai W; Lorvidhaya V
J Gynecol Oncol; 2019 Jul; 30(4):e82. PubMed ID: 31074236
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes and Sites of Failure in Locally Advanced, Cervical Cancer Patients Treated by Concurrent Chemoradiation with or without Adjuvant Chemotherapy: ACTLACC Trial.
Tovanabutra C; Asakij T; Rongsriyam K; Tangjitgamol S; Tharavichitkul E; Sukhaboon J; Kridakara LCA; Paengchit K; Khunnarong J; Atjimakul T; Pariyawateekul P; Tanprasert P; Tungkasamit T; Lorvidhaya V
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2977-2985. PubMed ID: 34582670
[TBL] [Abstract][Full Text] [Related]
7. Role of adjuvant chemotherapy after concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Kou L; Zhang T; Yang X; Peng S; Wang Y; Yuan M; Li M
Future Oncol; 2022 May; 18(16):1917-1915. PubMed ID: 35193379
[No Abstract] [Full Text] [Related]
8. Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
Phippen NT; Leath CA; Chino JP; Jewell EL; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2012 Nov; 127(2):267-72. PubMed ID: 22892361
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer.
Katanyoo K; Chitapanarux I; Tungkasamit T; Chakrabandhu S; Chongthanakorn M; Jiratrachu R; Kridakara A; Townamchai K; Muangwong P; Tovanabutra C; Chomprasert K
J Gastrointest Oncol; 2018 Jun; 9(3):425-434. PubMed ID: 29998007
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis.
Liu H; Ma X; Sun C; Wu M; Xu Z; Zhou S; Yao N; Liu S; Qin X; Han Z
Front Oncol; 2022; 12():997030. PubMed ID: 36568251
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups.
Todo Y; Watari H
Chin J Cancer Res; 2016 Apr; 28(2):221-7. PubMed ID: 27199520
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.
Mehra R; Yong C; Seal B; van Keep M; Raad A; Zhang Y
J Natl Compr Canc Netw; 2021 Feb; 19(2):153-162. PubMed ID: 33545688
[TBL] [Abstract][Full Text] [Related]
13. MRI radiomics in overall survival prediction of local advanced cervical cancer patients tread by adjuvant chemotherapy following concurrent chemoradiotherapy or concurrent chemoradiotherapy alone.
Wei G; Jiang P; Tang Z; Qu A; Deng X; Guo F; Sun H; Zhang Y; Gu L; Zhang S; Mu W; Wang J; Tian J
Magn Reson Imaging; 2022 Sep; 91():81-90. PubMed ID: 35636572
[TBL] [Abstract][Full Text] [Related]
14. Is There a Place for Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer?
Čerina D; Boraska Jelavić T; Buljubašić Franić M; Tomić K; Bajić Ž; Vrdoljak E
Curr Oncol; 2022 Jul; 29(8):5223-5237. PubMed ID: 35892984
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
16. Correlations between alterations of T-helper 17 cells and treatment efficacy after concurrent radiochemotherapy in locally advanced cervical cancer (stage IIB-IIIB): a 3-year prospective study.
Liu Y; Guo QF; Chen JL; Li XR; Hou F; Liu XY; Zhang WJ; Zhang Y; Gao FF; Zhang YZ; Cui BX; Liu NF
Chin Med J (Engl); 2021 Apr; 134(8):954-962. PubMed ID: 33840740
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of concurrent chemoradiation in comparison with radiation alone in locally advanced cervical cancer.
Manusirivithaya S; Sripramote M; Tangjitgamol S; Sanjareonsuttikul N; Pisarnturakit P
J Med Assoc Thai; 2005 Aug; 88(8):1035-44. PubMed ID: 16404829
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Brachytherapy; 2015; 14(1):29-36. PubMed ID: 25443528
[TBL] [Abstract][Full Text] [Related]
19. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: A single-institutional retrospective study from a prospective database.
Liu B; Li L; Wang M; Wei L; Li J; Zou W; Lv Y; Zhang H; Liu S
Gynecol Oncol; 2019 Sep; 154(3):583-589. PubMed ID: 31307665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
